Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 7/2020

01-07-2020 | Obesity | Review

Revisiting the Ghrelin Changes Following Bariatric and Metabolic Surgery

Authors: Carlota Tuero, Victor Valenti, Fernando Rotellar, Manuel F. Landecho, Javier A. Cienfuegos, Gema Frühbeck

Published in: Obesity Surgery | Issue 7/2020

Login to get access

Abstract

Since the description of ghrelin in 1999, several studies have dug into the effects of this hormone and its relationship with bariatric surgery. While some aspects are still unresolved, a clear connection between ghrelin and the changes after metabolic surgery have been established. Besides weight loss, a significant amelioration in obesity-related comorbidities following surgery has also been reported. These changes in patients occur in the early postoperative period, before the weight loss appears, so that amelioration may be mainly due to hormonal changes. The purpose of this review is to go through the current body of knowledge of ghrelin’s physiology, as well as to update and clarify the changes that take place in ghrelin concentrations following bariatric/metabolic surgery together with their potential consolidation to outcomes.
Literature
1.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature [Internet]. 1999 [cited 2017 Nov 12];402:656–660. Available from: https://​doi.​org/​10.​1038/​45230
2.
3.
Delporte C, Christine. Structure and physiological actions of ghrelin. Scientifica (Cairo) [Internet]. 2013;2013:518909. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​24381790%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3863518
4.
5.
6.
Gauna C, van de Zande B, van Kerkwijk A, Themmen APN, van der Lely AJ, Delhanty PJD. Unacylated ghrelin is not a functional antagonist but a full agonist of the type 1a growth hormone secretagogue receptor (GHS-R). Mol Cell Endocrinol [Internet]. 2007 [cited 2017 Nov 11];274:30–4. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​17601657
7.
Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab [Internet]. 2002 [cited 2017 Nov 12];87:2988–2988. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12050285
8.
Monteleone P, Bencivenga R, Longobardi N, et al. Differential responses of circulating ghrelin to high- fat or high-carbohydrate meal in healthy women. J Clin Endocrinol Metab. 2003;88:5510–4.PubMed
9.
Zhao T-J, Sakata I, Li RL, et al. Ghrelin secretion stimulated by β1-adrenergic receptors in cultured ghrelinoma cells and in fasted mice. PNAS. 2010;107:15868–73.PubMed
10.
11.
Maja S, Engelstoft W-m P, Sakata I, et al. Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. Mol Metab. 2013;2:376–92.
12.
13.
14.
Goebel-Stengel M, Hofmann T, Elbelt U, Teuffel P, Ahnis A, Kobelt P, et al. The ghrelin activating enzyme ghrelin-O-acyltransferase (GOAT) is present in human plasma and expressed dependent on body mass index. Peptides [Internet]. 2013 [cited 2017 Nov 11];43:13–9. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23454172
15.
16.
17.
18.
Khatib MN, Gaidhane S, Gaidhane AM, et al. Ghrelin O acyl transferase (GOAT) as a novel metabolic regulatory enzyme. J Clin Diagnostic Res. 2015;9:LE01–5.
19.
20.
21.
22.
23.
Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, et al. Obestatin promotes survival of pancreatic -cells and human islets and induces expression of genes involved in the regulation of -cell mass and function. Diabetes [Internet]. 2008 [cited 2018 Mar 4];57:967–79. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18162507
24.
25.
Huda MSB, Durham BH, Wong SP, Deepak D, Kerrigan D, McCulloch P, et al. Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes [Internet]. 2008 [cited 2017 Nov 7];32:129–35. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​17667911
26.
Martins C, Kjelstrup L, Mostad IL, et al. Impact of sustained weight loss achieved through Roux-en-Y gastric bypass or a lifestyle intervention on ghrelin, obestatin, and ghrelin/obestatin ratio in morbidly obese patients. Obes Surg. 2011;21:751–8.PubMed
27.
Roth CL, Reinehr T, Schernthaner G-H, Kopp H-P, Kriwanek S, Schernthaner G. Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery. Obes Surg [Internet]. 2009 [cited 2017 Nov 11];19:29–35. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18521699
28.
29.
30.
Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, Weigle DS. Postprandial Suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab [Internet]. 2004 [cited 2017 Dec 11];89:1319–24. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15001628
31.
32.
33.
34.
35.
Hooper LE, Foster-Schubert KE, Weigle DS, Sorensen B, Ulrich CM, McTiernan A. Frequent intentional weight loss is associated with higher ghrelin and lower glucose and androgen levels in postmenopausal women. Nutr Res [Internet]. 2010 [cited 2017 Nov 1];30:163–70. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20417876
36.
37.
38.
39.
Rhea EM, Salameh TS, Logsdon AF, et al. Blood-brain barriers in obesity. AAPS. 2017;19:921–30.
40.
Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med [Internet]. 2011 [cited 2017 Nov 1];365:1597–604. Available from: https://​doi.​org/​10.​1056/​NEJMoa1105816
41.
Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 2006;89:71–84.PubMed
42.
Nymo S, Coutinho SR, Eknes PH, et al. Investigation of the long-term sustainability of changes in appetite after weight loss. Int J Obes. 2018;42:1489–99.
43.
Iepsen EW, Lundgren J, Holst JJ, et al. Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY. Eur J Endocrinol. 2016;174:775–84.PubMed
44.
Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, Gfrerer L, Ludvik B, Zacherl J, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg [Internet]. 2010 [cited 2017 Dec 3];20:535–40. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20094819
45.
Xu HC, Pang YC, Chen JW, et al. Systematic review and meta-analysis of the change in ghrelin levels after Roux-en-Y gastric bypass. Obes Surg. 2019;29:1343–51.PubMed
46.
Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab [Internet]. 2001 [cited 2017 Oct 31];86:5083–5083. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​11600590
47.
Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab [Internet]. 2004 [cited 2017 Nov 13];89:3062–5. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15181099
48.
Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010;59:2145–51.PubMedPubMedCentral
49.
50.
Sun Y, Asnicar M, Saha PK, et al. Ablation of ghrelin improves the diabetic but not obese phenotype of Ob/ob mice. Cell Metab. 2006;3:379–86.PubMed
51.
Tamboli RA, Antoun J, Sidani RM, et al. Metabolic responses to exogenous ghrelin in obesity and early after Roux-en-Y gastric bypass in humans. Diabetes Obes Metab. 2017;19:1267–75.PubMedPubMedCentral
52.
Zhao T-J, Liang G, Li RL, Xie X, Sleeman MW, Murphy AJ, et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci [Internet]. 2010 [cited 2017 Oct 31];107:7467–72. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20231469
53.
54.
Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest. 2006;116:1983–93.PubMedPubMedCentral
55.
Frühbeck G, Méndez-Giménez L, Fernández-Formoso JA, et al. Regulation of adipocyte lipolysis. Nutr Res. 2014;27:63–93.
56.
Miao H, Pan H, Wang L, et al. Ghrelin promotes proliferation and inhibits differentiation of 3T3-L1 and human primary preadipocytes. Front Physiol. 2019;10:1296.PubMedPubMedCentral
57.
Heppner KM, Piechowski CL, Müller A, Ottaway N, Sisley S, Smiley DL, et al. Both acyl and des-acyl ghrelin regulate adiposity and glucose metabolism via central nervous system ghrelin receptors. Diabetes [Internet]. American Diabetes Association; 2014 [cited 2017 Oct 26];63:122–31. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​24062249
58.
Gómez-Ambrosi J, Catalán V, Rodríguez A, et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care. 2014;37:2813–21.PubMed
59.
Ezquerro S, Mocha F, Frühbeck G, et al. Ghrelin reduces TNF-α-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD. J Clin Endocrinol Metab. 2019;104:21–37.PubMed
60.
61.
62.
Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation [Internet]. 2004 [cited 2017 Oct 25];110:3674–9. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15569841
63.
Gaigai Zhang, Xinhua Yin, Yongfen Qi, Lakshmana Pendyala, Jack Chen, Dongming Hou and CT. Ghrelin and cardiovascular diseases. Curr Cardiol Rev 2010;6:62–70.
64.
Leonetti F, Silecchia G, Iacobellis G, Ribaudo MC, Zappaterreno A, Tiberti C, et al. Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab [Internet]. 2003 [cited 2017 Dec 5];88:4227–31. Available from: https://​doi.​org/​10.​1210/​jc.​2003-030133
65.
Ram E, Vishne T, Diker D, et al. Impact of gastric banding on plasma ghrelin, growth hormone, cortisol, DHEA and DHEA-s levels. Obes Surg. 2005;15:1118–23.PubMed
66.
Shak JR, Roper J, Perez-Perez GI, et al. The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg. 2004;18:1089–96.
67.
68.
69.
70.
Hady HR, Dadan JGP. 100 obese patients after laparoscopic adjustable gastric banding – the influence on BMI, gherlin and insulin concentration, parameters of lipid balance and co-morbidities. Adv Med Sci. 2012;57:58–64.PubMed
71.
Mariani LM, Fusco A, Turriziani M, et al. Transient increase of plasma ghrelin after laparoscopic adjustable gastric banding in morbid obesity. Horm Metab Res. 2005;37:242–5.PubMed
72.
Hanusch-Enserer U, Cauza E, Georg Brabant AD, et al. Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding. J Clin Endocrinol Metab. 2004;89:3352–8.PubMed
73.
Gelisgen R, Zengin K, Kocael A, et al. Effects of laparoscopic gastric band applications on plasma and fundic acylated ghrelin levels in morbidly obese patients. Obes Surg. 2012;22:299–305.PubMed
74.
Kruljac I, Mirošević G, Kirigin LS, et al. Changes in metabolic hormones after bariatric surgery and their predictive impact on weight loss. Clin Endocrinol. 2016;85:852–60.
75.
Schindler K, Prager G, Ballaban T, Kretschmer S, Riener R, Buranyi B, et al. Impact of laparoscopic adjustable gastric banding on plasma ghrelin, eating behaviour and body weight. Eur J Clin Invest [Internet]. 2004 [cited 2017 Dec 6];34:549–54. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15305889
76.
Frühbeck G, Rotellar F, Hernández-Lizoain JL, Gil MJ, Gómez-Ambrosi J, Salvador J, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg [Internet]. 2004 [cited 2017 Dec 3];14:1208–15. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15527636
77.
Tsouristakis AI, Febres G, Mcmahon DJ, et al. Long-term modulation of appetitive hormones and sweet cravings after adjustable gastric banding and Roux-en-Y gastric bypass. Obes Surg. 2019;29(11):3698–705
78.
79.
80.
Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg [Internet]. 2012 [cited 2017 Dec 3];22:740–8. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22354457
81.
82.
83.
Frühbeck G, Diez-Caballero A, Gil MJ, Montero I, Gómez-Ambrosi J, Salvador J, et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg [Internet]. 2004 [cited 2017 Dec 3];14:606–12. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15186626
84.
Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg [Internet]. 2014 [cited 2017 Dec 4];24:241–52. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23996294
85.
Alamuddin N, Vetter ML, Ahima RS, Hesson L, Ritter S, Minnick A, et al. Changes in fasting and prandial gut and adiposity hormones following vertical sleeve gastrectomy or Roux-en-Y-gastric bypass: an 18-month prospective study. Obes Surg [Internet]. 2017 [cited 2017 Dec 3];27:1563–72. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28004304
86.
Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy. Ann Surg [Internet]. 2008 [cited 2017 Dec 4];247:401–7. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18376181
87.
Ramón JM, Salvans S, Crous X, Puig S, Goday A, Benaiges D, et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg [Internet]. 2012 [cited 2017 Dec 4];16:1116–22. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22402955
88.
89.
90.
Braghetto I, Davanzo C, Korn O, Csendes A, Valladares H, Herrera E, et al. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg [Internet]. 2009 [cited 2017 Dec 5];19:1515–21. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​19714384
91.
Baumann T, Kuesters S, Grueneberger J, Marjanovic G, Zimmermann L, Schaefer A-O, et al. Time-resolved MRI after ingestion of liquids reveals motility changes after laparoscopic sleeve gastrectomy--preliminary results. Obes Surg [Internet]. 2011 [cited 2017 Dec 6];21:95–101. Available from: https://​doi.​org/​10.​1007/​s11695-010-0317-6
92.
93.
94.
95.
96.
Cummings DE, Shannon MH. Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab. 2003;88:2999–3002.PubMed
97.
98.
Peterli R, Wölnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy. Ann Surg [Internet]. 2009 [cited 2017 Dec 3];250:234–41. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​19638921
99.
100.
Tanya M, Halliday SP, Schoen JA, et al. Comparison of surgical versus diet-induced weight loss on appetite regulation and metabolic health outcomes. Physiol Rep. 2019;7:1–15.
101.
Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab [Internet]. 2005 [cited 2017 Dec 3];90:359–65. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15483088
102.
Holdstock C, Engström BE, Öhrvall M, Lind L, Sundbom M, Karlsson FA. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab [Internet]. 2003 [cited 2017 Dec 3];88:3177–83. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12843162
103.
Barazzoni R, Zanetti M, Nagliati C, Cattin MR, Ferreira C, Giuricin M, et al. Gastric bypass does not normalize obesity-related changes in ghrelin profile and leads to higher acylated ghrelin fraction. Obesity [Internet]. 2013 [cited 2017 Dec 3];21:718–22. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23712974
104.
Pérez-Romero N, Serra A, Granada ML, Rull M, Alastrué A, Navarro-Díaz M, et al. Effects of two variants of Roux-en-Y gastric bypass on metabolism behaviour: focus on plasma ghrelin concentrations over a 2-year follow-up. Obes Surg [Internet]. Springer-Verlag; 2010 [cited 2017 Dec 6];20:600–9. Available from: https://​doi.​org/​10.​1007/​s11695-009-0035-0
105.
le Roux CW, Neary NM, Halsey TJ, Small CJ, Martinez-Isla AM, Ghatei MA, et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab [Internet]. 2005 [cited 2017 Dec 6];90:4521–4. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15914532
106.
Maier C, Schaller G, Buranyi B, Nowotny P, Geyer G, Wolzt M, et al. The cholinergic system controls ghrelin release and ghrelin-induced growth hormone release in humans. J Clin Endocrinol Metab [Internet]. 2004 [cited 2017 Dec 6];89:4729–33. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15356087
107.
108.
Faraj M, Havel PJ, Lis SP, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab [Internet]. 2003 [cited 2017 Dec 3];88:1594–602. Available from: https://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12679444
109.
Topart PA, Becouarn G. Revision and reversal after biliopancreatic diversion for excessive side effects or ineffective weight loss: a review of the current literature on indications and procedures. Surg Obes Relat Dis [Internet]. 2015 [cited 2017 Dec 6];11:965–72. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25726366
110.
111.
Garcia-Fuentes E, Garrido-Sanchez L, Garcia-Almeida JM, et al. Different effect of laparoscopic Roux-en-Y gastric bypass and open biliopancreatic diversion of Scopinaro on serum PYY and ghrelin levels. Obes Surg. 2008;18:1424–19.PubMed
112.
Marina Tsoli, Aikaterini Chronaiou, Ioannis Kehagias, Fotis Kalfarentzos TKA. Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surg Obes Relat Dis 2013;9:667–678.
113.
114.
Santiago-Fernández C, García-Serrano S, Tome M, et al. Ghrelin levels could be involved in the improvement of insulin resistance after bariatric surgery. Endocrinol Diabetes Nutr. 2017;64:355–62.PubMed
115.
García-Unzueta MT, Fernández-Santiago R, Domínguez-Díez A, Vazquez-Salví L, Fernández-Escalante JC, Amado JA. Fasting plasma ghrelin levels increase progressively after biliopancreatic diversion: one-year follow-up. Obes Surg [Internet]. 2005 [cited 2017 Dec 6];15:187–90. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15802059
116.
117.
Kotidis E V, Koliakos G, Papavramidis TS, Papavramidis ST. The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight-reducing effect of this procedure? Obes Surg [Internet]. 2006 [cited 2017 Dec 6];16:554–9. Available from: https://​doi.​org/​10.​1381/​0960892067769449​40
118.
Liou J-M, Lin J-T, Lee W-J, et al. The serial changes of ghrelin and leptin levels and their relations to weight loss after laparoscopic minigastric bypass surgery. Obes Surg. 2008;18:84–9.PubMed
119.
120.
121.
122.
123.
le Roux CW, Bueter M, Theis N, Werling M, Ashrafian H, Löwenstein C, et al. Gastric bypass reduces fat intake and preference. Am J Physiol Regul Integr Comp Physiol [Internet]. American Physiological Society; 2011 [cited 2017 Dec 6];301:R1057-66. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21734019
124.
Faulconbridge LF, Ruparel K, Loughead J, Allison KC, Hesson LA, Fabricatore AN, et al. Changes in neural responsivity to highly palatable foods following Roux-en-Y gastric bypass, sleeve gastrectomy, or weight stability: an fMRI study. Obesity [Internet]. 2016 [cited 2017 Dec 4];24:1054–60. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27112067
125.
126.
Redman LM, Heilbronn LK, Martin CK, de Jonge L, Williamson DA, Delany JP, et al. Metabolic and behavioral compensations in response to caloric restriction: implications for the maintenance of weight loss. Wang C, editor. PLoS One [Internet]. 2009 [cited 2017 Dec 6];4:e4377. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​19198647
127.
128.
Makaronidis JM, Neilson S, Cheung W-H, Tymoszuk U, Pucci A, Finer N, et al. Reported appetite, taste and smell changes following Roux-en-Y gastric bypass and sleeve gastrectomy: effect of gender, type 2 diabetes and relationship to post-operative weight loss. Appetite [Internet]. 2016 [cited 2018 Mar 3];107:93–105. Available from: http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S019566631630298​7
129.
Stice E, Spoor S, Bohon C, Veldhuizen MG, Small DM. Relation of reward from food intake and anticipated food intake to obesity: a functional magnetic resonance imaging study. J Abnorm Psychol [Internet]. 2008 [cited 2017 Dec 6];117:924–35. Available from: https://​doi.​org/​10.​1037/​a0013600
130.
131.
132.
Blackburn AN, Hajnal ALL. The gut in the brain: the effects of bariatric surgery on alcohol consumption. Addict Biol. 2017;22:1540–53.PubMed
133.
Azam H, Shahrestani S, Phan K. Alcohol use disorders before and after bariatric surgery: a systematic review and meta-analysis. Ann Transl Med. 2018;6:148.PubMedPubMedCentral
134.
Hajnal A, Zharikov A, Polston JE, et al. Alcohol reward is increased after Roux-en-Y gastric bypass in dietary obese rats with differential effects following ghrelin antagonism. PLoS One. 2012;7:e49121.PubMedPubMedCentral
135.
James E, Mitchell RC, de Zwaan M, et al. Possible risk factors of increased suicide following bariatric surgery. Obesity (Silver Spring). 2013;21:665–72.
136.
Farokhnia M, Faulkner ML, Piacentino D, et al. Ghrelin: from a gut hormone to a potential therapeutic target for alcohol use disorder. Physiol Behav. 2019;204:49–57.PubMed
137.
Wittekind DA, Kratzsch J, Mergl R, et al. Alcohol consumption is positively associated with fasting serum ghrelin in non-dependent adults: results from the population-based LIFE-adult-study. Psychoneuroendocrinology. 2018;97:143–8.PubMed
138.
Orellana ER, Jamis C, Horvath NHA. Effect of vertical sleeve gastrectomy on alcohol consumption and preferences in dietary obese rats and mice: a plausible role for altered ghrelin signaling. Brain Res Bull. 2018;138:26–36.PubMed
139.
Neovius M, Bruze G, Jacobson P, et al. Bariatric Surgery & Suicide: Results from two controlled matched cohort studies. Lancet Diabetes Endocrinol. 2018;6:197–207.PubMedPubMedCentral
140.
141.
Lutter M, Sakata I, Osborne-Lawrence S, et al. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci. 2008;11:752–3.PubMedPubMedCentral
142.
Kluge M, Schüssler P, Dresler M, et al. Effects of ghrelin on psychopathology, sleep and secretion of cortisol and growth hormone in patients with major depression. J Psychiatr Res. 2011;45:421–6.PubMed
143.
Jensen M, Ratner C, Rudenko O, et al. Anxiolytic-like effects of increased ghrelin receptor signaling in the amygdala. Int J Neuropsychopharmacol. 2015;19:1–12.
144.
145.
146.
Vlasova MA, Järvinen KHK. Cardiovascular effects of ghrelin antagonist in conscious rats. Regul Pept. 2009;156:72–6.PubMed
147.
Beheshti SAN. Local injection of d-lys-3-GHRP-6 in the rat amygdala, dentate gyrus or ventral tegmental area impairs memory consolidation. Neuropeptides. 2018;67:20–6.PubMed
148.
Puzio I, Piedra JLV, Kapica M, et al. Influence of intragastric administration of ghrelin receptor antagonist [D-LYS3]-GHRP-6 on bone tissue in rats. Bull Vet Inst Pulawy. 2011;55:501–5.
149.
Biotechnology C. Phase I/IIa clinical trial with obese individuals shows no effect of CYT009-GhrQb on weight loss. Cytos Biotechnol Press release. 7
150.
Denney WS, Sonnenberg GE, Carvajal-Gonzalez S, et al. Pharmacokinetics and pharmacodynamics of PF-05190457: the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. Br J Clin Pharmacol. 83:326–38.
Metadata
Title
Revisiting the Ghrelin Changes Following Bariatric and Metabolic Surgery
Authors
Carlota Tuero
Victor Valenti
Fernando Rotellar
Manuel F. Landecho
Javier A. Cienfuegos
Gema Frühbeck
Publication date
01-07-2020
Publisher
Springer US
Published in
Obesity Surgery / Issue 7/2020
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-020-04601-5

Other articles of this Issue 7/2020

Obesity Surgery 7/2020 Go to the issue

Brief Communication

Inclusion of a Clip Inside the Cartridge and Failure of the Stapler When Performing a Laparoscopic Sleeve Gastrectomy

Original Contributions

Value-Based Healthcare and Enhanced Recovery After Surgery Implementation in a High-Volume Bariatric Center in Italy

Original Contributions

Predicting Weight Loss and Comorbidity Improvement 7 Years Following Laparoscopic Sleeve Gastrectomy: Does Early Weight Loss Matter?

Original Contributions

SERPINE-1 Gene Methylation and Protein as Molecular Predictors of Laparoscopic Sleeve Gastrectomy Outcome

Letter to the Editor

Letter to the Editor Concerning: Conversion of One Anastomosis Gastric Bypass (OAGB) to Roux-en-Y Gastric Bypass (RYGB) for Biliary Reflux Resistant to Medical Treatment: Lessons Learned from a Retrospective Series of 2780 Consecutive Patients Undergoing OAGB

Original Contributions

Ileal Transposition in Rats Reduces Energy Intake, Body Weight, and Body Fat Most Efficaciously When Ingesting a High-Protein Diet